DiaMedica Therapeutics (DMAC) Consolidated Net Income: 2018-2019
Historic Consolidated Net Income for DiaMedica Therapeutics (DMAC) over the last 2 years, with Dec 2019 value amounting to -$2.5 million.
- DiaMedica Therapeutics' Consolidated Net Income fell 26.40% to -$2.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$10.6 million, marking a year-over-year decrease of 85.72%. This contributed to the annual value of -$24.4 million for FY2024, which is 26.12% down from last year.
- Latest data reveals that DiaMedica Therapeutics reported Consolidated Net Income of -$2.5 million as of Q4 2019, which was down 1.31% from -$2.4 million recorded in Q3 2019.
- DiaMedica Therapeutics' 5-year Consolidated Net Income high stood at -$650,000 for Q1 2018, and its period low was -$3.3 million during Q1 2019.
- Over the past 2 years, DiaMedica Therapeutics' median Consolidated Net Income value was -$2.2 million (recorded in 2018), while the average stood at -$2.0 million.
- Data for DiaMedica Therapeutics' Consolidated Net Income shows a maximum YoY plummeted of 400.31% (in 2019) over the last 5 years.
- Quarterly analysis of 2 years shows DiaMedica Therapeutics' Consolidated Net Income stood at -$2.0 million in 2018, then decreased by 26.40% to -$2.5 million in 2019.
- Its Consolidated Net Income stands at -$2.5 million for Q4 2019, versus -$2.4 million for Q3 2019 and -$2.5 million for Q2 2019.